Figitumumab (CP-751,871) for cancer therapy, PMID: 20175655
Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer, PMID: 19632947
Retraction. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab, PMID: 23211971
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer, PMID: 21748299
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial, PMID: 24488322
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy, PMID: 28427155
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies, PMID: 21777167
The failure of figitumumab: the danger of taking shortcuts in drug development, PMID: 25524479
Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer, PMID: 21149666
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871), PMID: 24107449
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer, PMID: 24888810
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer, PMID: 25395283
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma, PMID: 19649631
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors, PMID: 27733479
In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib, PMID: 26195122
Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02), PMID: 22234739
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer, PMID: 22553344
Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants, PMID: 23400740
Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys, PMID: 20540090
The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer, PMID: 25806342
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer, PMID: 24536060
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors, PMID: 21177764
Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC, PMID: 27488947
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study, PMID: 20036194
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab, PMID: 21102589
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response, PMID: 20457621
The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status, PMID: 21642381
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma, PMID: 22025154
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study, PMID: 20628389
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer, PMID: 26287334
Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma, PMID: 25358597
Emerging therapeutic targets for synovial sarcoma, PMID: 24661286
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab, PMID: 21720213
IGFBP, a novel target of lung cancer?, PMID: 28104361
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin, PMID: 19745765
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody, PMID: 22438913
Minireview: Were the IGF Signaling Inhibitors All Bad?, PMID: 26366975
Clinical relevance of monoclonal antibodies in non small cell lung cancer, PMID: 19785057
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments, PMID: 33467481
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer, PMID: 20367288
Advances in antibody therapeutics targeting small-cell lung cancer, PMID: 29790694
Targeting receptor tyrosine kinases in gastric cancer, PMID: 24782606
Insulin-like growth factor receptor inhibitors: baby or the bathwater?, PMID: 22761272
Targeting the insulin growth factor pathway in gastrointestinal cancers, PMID: 21717907
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy, PMID: 24033707
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors, PMID: 21907495
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC), PMID: 21715100
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade, PMID: 26429980
Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh, PMID: 20676809
For research use only. Not for human or drug use.
